Table 3 Regional differences in fulfilment of classification criteria
Number of patients included | Patients fulfilling Amor criteria, n (%) | Patients fulfilling mAmor criteria, n (%) | Patients fulfilling ESSG criteria, n (%) | Patients fulfilling mESSG criteria, n (%) | Total patients fulfilling ASAS SpA criteria, n (%) | Patients fulfilling ASAS axSpAcriteria, n (%) | Patients fulfilling, ASAS pSpA criteria, n (%) | Patients fulfilling CASPAR criteria, n (%) | |
|---|---|---|---|---|---|---|---|---|---|
Western Europe | 1507 | 1242 (82.4%) | 1333 (88.5%) | 1335 (88.6%) | 1433 (95.1%) | 1305 (86.6%) | 1149 (76.2%) | 156 (10.4%) | 388 (25.7%) |
Central Europe | 438 | 342 (78.1%) | 364 (83.1%) | 402 (91.8%) | 419 (95.7%) | 391 (89.3%) | 368 (84.0%) | 23 (5.3%) | 32 (7.3%) |
North America | 239 | 203 (84.9%) | 205 (85.8%) | 219 (91.6%) | 219 (91.6%) | 176 (73.6%) | 122 (51.0%) | 54 (22.6%) | 120 (50.2%) |
Latin America | 348 | 290 (83.3%) | 307 (88.2%) | 314 (90.2%) | 326 (93.7%) | 280 (80.5%) | 239 (68.7%) | 41 (11.8%) | 93 (26.7%) |
North Africa | 337 | 300 (89.0%) | 310 (92.0%) | 316 (93.8%) | 324 (96.1%) | 308 (91.4%) | 260 (77.2%) | 48 (14.2%) | 94 (27.9%) |
Asia | 1073 | 905 (84.3%) | 935 (87.1%) | 899 (83.8%) | 931 (86.8%) | 910 (84.8%) | 817 (76.1%) | 93 (8.7%) | 125 (11.6%) |